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Abstract 
 
Objective: The objective of this systematic review is to determine whether or not “how safe and 
effective is infliximab in treatment of children with moderate to severe Crohn’s disease?” 
 
Study Design: Review of three English language primary studies published in 2007, 2009 and 
2009.  
 
Data Sources: Two randomized control trials and a cohort study measuring the safety and 
efficacy of infliximab therapy in children with Crohn’s disease were found by using PubMed and 
Cochrane databases 
 
Outcome(s) Measured: The outcomes measured in the studies were clinical response and 
clinical remission. The Hyams et al 2007 study determined clinical response and remission by 
the Pediatric Crohn’s Disease Activity Index (PCDAI). The Ruemmele et al study measured 
clinical remission by Harvey Bradshaw Index (HBI) and Erythrocyte Sedimentation Rate (ESR). 
In the Hyams et al 2009 study, the Physician Global Assessment (PGA) was used to measure 
clinical response and clinical remission.  
 
Results: All three studies showed that infliximab is safe and effective against Crohn’s disease in 
the pediatric population. The Ruemmele et al study demonstrated that a scheduled 2-month 
therapy was better than an on demand therapy in the number of clinical responses and 
remissions. The Hyams et al 2007 study showed that more patients were more likely to be in 
clinical response and remission if therapy was given every 8 weeks rather than every 12 weeks.  
 
Conclusions: Infliximab is a safe and effective treatment in the treatment of children with 
moderate to severe Crohn’s disease according to the results of the three studies in this review 
 
Key words: pediatric Crohn’s disease, infliximab 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Linh, Infliximab and Pediatric Crohn’s, 2 
Introduction: 
Crohn’s disease is a chronic inflammatory bowel disease (IBD), which is characterized 
by transmural inflammation skip lesions with a cobblestone appearance that can affect any part 
of the GI tract, but commonly the terminal ileum. Crohn’s disease has no known cause, but may 
have some genetic link such as first-degree relatives and environmental factors including 
smoking. Crohn’s disease has a higher rate in Caucasians and Ashkenazi Jews. Its peak incidence 
is between the age of 15-35 and 50-70.
1 
 
Signs and symptoms depend on the severity and location of the disease. Symptoms can 
include malaise, fatigue, abdominal pain, nonbloody diarrhea, and fecal urgency. Signs include 
fever, weight loss, abdominal tenderness/distention, hepatospleenomegaly, hyperactive bowel 
sounds, perianal fistulas, and abscess. There can be extraintestinal signs and symptoms such as 
oral aphthous ulcers, erythema nodosum, pyoderma gangrenosum, iritis, uvetitis, and arthrithis.
1,2 
 
 Crohn’s disease is typically treated non-pharmacologically and/or pharmacologically. 
Surgery is another option, but it does not cure the disease. A well-balanced diet with high fiber, 
low fat, and low roughage may be beneficial to patients. Analgesics such as acetaminophen and 
anti-diarrheals can provide symptomatic relief. Antibiotics such as metronidazole can be given to 
treat bacterial overgrowth in the intestines. Corticosteroids and 5-Aminosalicyclic acid (5-ASA) 
are used to treat inflammation. When patients do not receive relief with corticosteroids or 5-
ASA, immunomodulator drugs are used such as azathioprine and mercaptopurine, which blocks 
the reaction that cause inflammation in the body.
1
 Infliximab, which is a monoclonal antibody 
against tumor necrosis factor alpha, is used when conventional therapy fails or in refractory cases 
usually in moderate to severe Crohn’s disease.1,2 Research suggests infliximab may provide 
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satisfactory treatment and maintenance for moderate to severe Crohn’s disease in children., 
which is essential since Crohn’s disease is incurable. 
 It is estimated that IBD affects about 1 million people in the United States, and an 
estimated 500,000 of those Americans has Crohn’s disease, with 10% of this population 
affecting people under the age of 18.
3,4
 It is estimated that 25% of new diagnoses of 
inflammatory bowel disease occur in patients younger than 20 years of age.
5
 Depending on the 
severity of the disease and the treatments, it is estimated to an annual cost of $19,000 for a 
Crohn’s disease patient.6 Crohn’s disease patients contribute to 716,000 ambulatory care visits 
and 82,000 hospitalizations in 2004.
4
 Physician assistants nationwide can encounter patients with 
Crohn’s disease not only in primary care but also in the emergency room and operation room 
depending on the severity of the disease. Physician assistants in primary care, such as pediatrics, 
internal medicine, and family medicine, play an important role in educating the patient about the 
disease, its treatment, management, and complications.  
Objective: 
 The objective of this systematic review is to determine “how safe and effective is 
infliximab in the treatment of children with moderate to severe Crohn’s disease?” 
Methods: 
 All three studies, two randomized controlled trials and one cohort study, used in this 
selective review included the population of patients diagnosed with moderate to severe Crohn’s 
disease under the age of 18. The intervention used in the studies was IV infliximab 5mg/kg. The 
demographics and characteristics of each study are displayed in Table 1. For the study by 
Ruemmele et al, the comparison groups were patients who received infliximab on a fixed 
schedule of 2 months and patients who received infliximab on an on demand basis where there 
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were signs of relapse. Patients were given infliximab infusions at week 0, 2, 6, and then only the 
patients who had a clinical remission at week 10 where they were randomized into the group 
with scheduled therapy every 2 months or the on demand group.
7
 In the Hyams et al 2007 study, 
the comparison groups were patients who received infliximab every 8 weeks and patients who 
received infliximab every 12 weeks.
5
 Patients were given infliximab infusions at week 0, 2, 6, 
and then only the patients who responded to treatment at week 10 were randomized to infliximab 
every 8 or 12 weeks. There was no comparison group for the Hyams et al 2009 study. The 
outcomes measured were clinical response and clinical remission in the Hyams et al 2007 and 
2009 studies, and the outcome measured was only clinical remission in the Ruemmele et al 
study. Clinical response and clinical remission qualify as patient orientated evidence that matters 
(POEM).   
 Key words used in the searches were “pediatric Crohn’s disease and infliximab.” All 
articles searched were published in peer-reviewed journals in the English language. The author 
searched the articles through PubMed and Cochrane databases. The articles were selected based 
on the importance to patient (POEM). Inclusion criteria for this review were randomized 
controlled trials and cohort studies based outcomes relevant to the patient (POEM) and patients 
<18 years old diagnosed with moderate to severe Crohn’s disease. Exclusion criteria for this 
review were individuals over the age of 18 and articles written before the year 2004 due to a 
student in the 2004 with a similar topic. The statistics reported in the studies were p-values, 
relative risk reduction (RRR), absolute risk reduction (ARR), numbers needed to treat (NNT), 
and numbers needed to harm (NNH).  
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Table 1-Demographics & Characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Intervention 
Ruemmele, 
2009 (1) 
Randomiz
ed 
multicent
er open-
label trial 
40 7-17 Diagnosis of 
Crohn’s disease 6 
mos prior to trial; 
mod to severe 
Crohn’s disease; 
non-stricturing 
non-penetrating 
and penetrating 
disease; prior 
resistance to a 
combo therapy of 
an 
immunosuppressio
n 
Previous 
treatment 
of 
infliximab 
or any 
other anti-
tumor 
necrosis 
factor 
9 Infliximab 
5mg/kg at 
week 0, 2, 6; 
those who 
had a clinical 
remission 
and steroid 
withdrawal 
were 
randomized 
to either 
subsequent 
infliximab 
every 2 mos 
or a on 
demand basis 
Hyams, 
2007 (2) 
RCT 112 6-17 Pts 9-17 y/o with a 
PCDAI score >30 
at baseline; 
initiated tx with an 
immunomodulator 
at least 8 weeks 
before screening, 
and were to have 
been receiving a 
stable dose for at 
least the previous 
2 weeks 
Pts who 
had 
received 
previous 
treatment 
of 
infliximab 
or any 
other 
agent 
aimed at 
lowering 
TNF 
24 Infliximab 5 
mg/kg at 
weeks 0, 2, 
and 6; those 
who had a 
clinical 
response at 
week 10 
were 
randomized 
to receive 
either 
subsequent 
infliximab 
every 8 or 12 
weeks 
Hyams, 
2009 (3) 
Cohort 
study 
202 <16 Children under the 
age of 16 who are 
newly diagnosed 
with Crohn’s 
disease 
 
N/A N/A Infliximab 
maintenance 
therapy 
defined as 
either an 
increased 
dose or a 
decreased 
interval 
between 2  
doses  
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Outcomes Measured: 
 The outcomes measured in all three studies were based on POEMS, which were clinical 
response and clinical remission. The Hyams et al 2007 study determined clinical response and 
remission by the Pediatric Crohn’s Disease Activity Index (PCDAI). Clinical response is a 
decrease from baseline of >15 points and a total score of <30 points. Clinical remission is a 
PCDAI score of <10 points.
5
 The Ruemmele et al study measured clinical remission by the 
Harvey Bradshaw Index (HBI) <5 and Erythrocyte Sedimentation Rate (ESR) <20 mm/h.
7
 In the 
Hyams et al 2009 study, the Physician Global Assessment (PGA) was used to measure clinical 
response and clinical remission. Clinical response was defined as mild or inactive disease at 
every assessment while receiving infliximab without associated corticosteroid use or surgery.  
Clinical remission was defined as inactive disease at every assessment while receiving infliximab 
without associated corticosteroid use or surgery.
9
  
Results: 
 The Hyams et al 2007 was a multi-center randomized open-label study with outcomes 
that were presented as dichotomous data. All analyses were based on the intent-to-treat principle. 
The 112 patients in this study were given infliximab 5mg/kg at week 0, 2, and 6 and then were 
evaluated at week 10 if there was a clinical response. At week 10, the study showed at 95% CI 
between 82.5% and 94.3% that 99 out of the 112 patients  (88.4%) were in clinical response, and 
at 95% CI between 49.8% and 68% 66 of the 112 patients (63.5%) were in clinical remission. Of 
the 112 patients, 103 patients showed clinical response; 52 patients were randomized to the 
group (A) that will be receiving infliximab every 8 weeks and 51 patients were randomized to 
the group (B) that will be receiving infliximab every 12 weeks. The 9 patients that were not in 
clinical response received no further treatment with infliximab and were discontinued from the 
Linh, Infliximab and Pediatric Crohn’s, 7 
study. The number of patients either in clinical response or clinical remission for Group A and B 
along with p-values at week 54 is displayed in Table 2. More patients were in clinical response 
and clinical remission in Group A than the patients in Group B (Table 2). Patients in Group A 
trended towards a clinical response and clinical remission compared to patients in Group B based 
on the p-value=0.002 and p<0.001, respectively, which are both statistically significant.  In Table 
3, the NNT for clinical response and remission was calculated to be 4, which means we must 
treat 4 pediatric patients with Crohn’s disease with infliximab for 54 weeks in order to have 1 
patient in clinical response or clinical remission.
 
Table 2: Results of infliximab for the group receiving infliximab every 8 weeks and the group 
receiving infliximab every 12 weeks 
 Number of patients in 
clinical response at 
week 54 
Number of patients in 
clinical remission at 
week 54 
Infliximab every 8 
weeks (Group A) 
33 (63.5%) 29 (55.8%) 
Infliximab every 12 
weeks (Group B) 
17 (33.3%) 12 (23.5%) 
p-value p=0.002 P<0.001 
 
Table 3: Clinical Response and Remission-NNT 
 CER EER RRR ARR NNT 
Clinical 
Response 
23.5% 55.8% 137% 32.3% 4 
Clinical 
Remission 
33.3% 63.5% 90.6% 30.2% 4 
 
 Twenty-four out of the 112 patients discontinued from the study; nine patients 
discontinued the study before week 10 and 15 patients discontinued the study after week 10. 
Table 4 shows the safety findings for Group A and Group B. Patients in Group B had more 
patients who discontinued the study from adverse effects than patients in Group A, 4 (8.0%) and 
2 (3.8%), respectively. The most occurring safety parameter for both groups was infection; 
Group A has a higher incidence than Group B, 39 (73.6%) and 19 (38.0%), respectively; mostly 
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upper respiratory infections. However, the incidence of serious infections between Group A and 
Group B were similar. The NNH was calculated to be  -44, shown in Table 5, meaning the 
control condition is more likely to harm than the treatment condition, in this case the control 
group being Group B. 
Table 4: Summary of safety findings for all (112) patients through week 54 
Safety parameter Patients not 
randomized at week 
10 
Infliximab every 8 
weeks (Group A) 
Infliximab every 12 
weeks (Group B) 
Adverse event 9 (100%) 51 (96.2%) 46 (92.0%) 
Adverse events 
leading to 
discontinuation 
6 (66.7%) 2 (3.8%) 4 (8.0%) 
Serious adverse 
events 
7 (77.8%) 8 (15.1%) 7 (14.0%) 
Infection 3 (33.3%) 39 (73.6%) 19 (38.0%) 
Serious infection 2 (22.2%) 3 (5.7%) 4 (8.0%) 
Intestinal stenosis 2 (22.2%) 1 (1.9%) 0 (0.0%) 
Infusion reactions 1 (11.1%) 9 (17.0%) 9 (18.0%) 
Pneumonia 0 (0.0%) 2 (3.8%) 1 (2.0%) 
Herpes Zoster 0 (0.0%) 2 (3.8%) 0 (0.0%) 
 
Table 5: Number needed to harm 
CER EER RRI ARI NNH 
8% 5.7% -28.7% -2.3% -44 
 
 The Ruemmele et al study was a multi-center randomized open-label trial with outcomes 
that were presented as dichotomous data. Forty patients were given infliximab 5mg/kg at week 0, 
2, 6, and at week 10 patients who were in clinical remission and steroid withdrawal were 
randomized to either Group A, scheduled 2 week therapy, or Group B, an on demand basis with 
signs of relapse. At week 10, after the induction phase, 34 out of 40 patients (85%) were in 
clinical remission with a HBI mean drop of 6.7 + 2.5 to 1.1 + 1.5, with a p-value of <0.001. Nine 
out of the 40 patients did not reach clinical remission and/or had ESR >20mm/h at week 10, so 
18 patients were randomized to Group A and 13 patients were randomized to Group B. Patients 
in Group A had fewer patients experiencing a relapse than Group B, which is statistically 
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significant with a p-value<0.003 (Table 6). Group A also had more patients in clinical remission 
and a lower mean HBI than Group B, which is statistically significant with p<0.01 and p=0.011, 
respectively (Table 6). The NNT was calculated to be 5, shown in Table 7, which means we must 
treat 5 pediatric patients with Crohn’s disease with infliximab for 60 weeks in order to have 1 
patient in clinical remission. A total of 12 adverse events were reported during the study (Table 
8), but there were no serious adverse reactions or serious infectious complications that caused 
any patients to discontinue the study. The study also reported no difference in the number of 
adverse events between Group A and Group B.  
Table 6: Results of children receiving a 2week schedule and an on demand schedule 
 Number of children 
experiencing a relapse 
between week 10 and 
60 
Number of patients in 
clinical remission at 
week 60 
Mean HBI at week 60 
Schedule 2 week 
therapy (Group A) 
3 (23.1%) 15 (83%) 0.5 
On demand schedule 
with signs of relapse 
11 (92%) 8 (61%) 3.2 
p-value p<0.003 P<0.01 p=0.011 
 
Table 7: Number needed to treat-clinical remission  
 
 
 
 
Table 8: Adverse events 
Adverse 
Event 
Mild 
Headache 
Fever Rash Increased 
liver 
enzymes 
Neutropenia Joint/muscle 
pain 
# of 
patients 
3 3 3 1 1 1 
 
 The Hyams et al 2009 is a prospective, multi-center cohort study with outcomes that were 
presented as continuous data, but can be converted to dichotomous data. Disease severity by 
physician global assessment (PGA) was divided into inactive, mild, moderate, or severe. The 
CER EER RRR ARR NNT 
61.0% 83.0% 36.0% 22.0% 5 
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study included 729 patients, with 202 patients receiving infliximab categorized into maintenance, 
episodic or episodic converted into maintenance therapy. The percentage of patients in clinical 
response increased over 3 years, and the percentage of patients in clinical remission increased 
then decreased over 3 years (Table 9). The percentage of patients needed corticosteroids 
decreased over 2 years but increased slightly during the third year, which is statistically 
significant to baseline since p<0.001. The use of 6-MP/azathiopurine and immunomodulator 
decreased over 3 years, which is statistically significant with p<0.02 and p<0.01, respectively. 
The study reported no serious infections, but one patient had bowel associated Hodgkin’s 
lymphoma who was on 6-mercaptopurine and received 8 does of infliximab. 
Table 9: Results of infliximab therapy from year 0-3 
 6 months First Year Second Year Third Year p-value 
% of patients in 
clinical response 
 64% 70% 83%  
% of patients in 
clinical remission 
 26% 44% 33%  
% of patients 
receiving 
corticosteroids 
14% 8% 7% 9% P<0.001 
% of patients 
using 6-
MP/azathiopurine 
 74% 69% 58% P<0.02 
% of patients 
using 
immunomodulator  
87% 84% 82%% 75% P<0.01 
 
Discussion: 
 Crohn’s Disease is a chronic disease, so treating relapses and maintaining remission is 
extremely important. When Crohn’s disease is not treated properly, it can lead to serious 
complications such as small bowel obstruction, hemorrhage, abscess, and fistulas, which in turn 
can lead to more treatments and procedures and increasing the already high costs for patients. 
Infliximab, a monoclonal immunoglobulin antibody can alleviate the symptoms and assist in the 
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management of Crohn’s disease. Infliximab, which can also be used in rheumatoid arthritis, 
plaque psoriasis, and ulcerative colitis, was FDA approved for pediatric patients with Crohn’s 
disease in May 2006.
2
 There are still studies being conducted on this drug especially in children 
and its long term affects. Infliximab can increase a patient’s risk for serious infections especially 
if the patient is also receiving other immunosuppressive drugs. Infections were reported in the 
Hyams et al 2007 study, but the number of people who decided to discontinue the study because 
of an adverse event was significantly lower. Malignancy is also a concern, because there have 
been some reports of T-cell lymphoma in children receiving infliximab and azathioprine.
7
 The 
Hyams et al 2007 and Ruemmele et al study reported no malignancy in the patients, but the 
Hyams et al 2009 study reported one patient with bowel associated Hodgkin’s lymphoma. 
According to the results of Hyams et al 2007, Hyams et al 2009, and Ruemmele et al studies, 
there is evidence that infliximab is effective and safe for pediatric Crohn’s disease by the 
significant number of patients in either clinical response or clinical remission with a small 
percentage of serious adverse events in long term use.  
 There were some limitations among the three studies in this review. In the Ruemmele et 
al study, the sample size was small with 40 patients, which may not have represented the study 
population well enough. The Hyams et al 2007 study required patients to be on 
immunomodulator at least 8 weeks before the screening and at least on a stable dose for at the 2 
previous weeks. The results of this study such as clinical remission and clinical response may 
differ between patients that were not taking the same immunomodulator. The limitation in the 
Hyams et al study 2009 was that the inclusion criteria may have been too broad, children under 
the age of 16 who were newly diagnosed with Crohn’s disease, the results of the study may not 
be as specific to infliximab.  
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Conclusion: 
 Infliximab is a safe and effective treatment in children with moderate to severe Crohn’s 
disease according to the results demonstrated in the three studies in this review. Further study is 
needed to evaluate whether dependency and/or resistance can develop with the treatment of 
infliximab associated with treatment duration.  
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